We are proud of the clinical evidence, R&D achievements, and our five-year-long company development as Bluestar Genomics. Now, as a commercial-stage company, ClearNote Health continues to drive innovation in non-invasive cancer detection, with patient needs at the core of everything we pursue.
Based on more than 50,000 assays with samples collected across over 150 sites, we have produced multiple presentations and peer-reviewed papers including detection data from several cancer types, including pancreatic and ovarian.
